Septic shock: clinical, physiological, and pathological survey of 244 patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002302:Cardiac Output; D002512:Cephalothin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003091:Colistin / Q000627:therapeutic use; D003428:Cross Infection; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007612:Kanamycin / Q000627:therapeutic use; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010101:Oxygen Consumption; D010195:Pancreatitis / Q000209:etiology; D011704:Pyelonephritis / Q000150:complications; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000503:physiopathology; D013923:Thromboembolism / Q000473:pathology
D007612:Kanamycin; D002512:Cephalothin; D003091:Colistin